ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Renal Cell Carcinoma in Dialysis Patients: Criteria for Transplant Wait List Inclusion

D. B. Laskar1, J. Zeng1, S. Sharma2, M. T. Smith Jr3, A. D. Nicastri1, D. Levitan4, R. Maglantay1, D. John3, S. R. Gottesman1

1Pathology, SUNY Downstate Medical Center, Brooklyn, NY, 2Transplant Surgery, NYP/Columbia University Medical Center, New York, NY, 3Surgery, SUNY Downstate Medical Center, Brooklyn, NY, 4Pathology & Laboratory Medicine, NYP/Weill Cornell Medical Center, New York, NY

Meeting: 2019 American Transplant Congress

Abstract number: D388

Keywords: Kidney, Renal failure, Tumor recurrence, Waiting lists

Session Information

Session Name: Poster Session D: Late Breaking

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: End-stage renal disease (ESRD) patients on long-term hemodialysis have a higher incidence of renal cell carcinoma (RCC) in their native kidneys than the general population. Using ATS guidelines, most cancer diagnoses (e.g. breast, colon, etc.) require a cancer free period before the patient is eligible for transplant. Yet, low-stage RCC with tumor < 5 cm does not, based on the now disproven belief that RCC < 5 cm do not metastasize. Histologic subtype and tumor grade are also not considered in the eligibility criteria. With recently changed rules for acquiring waiting time, this may take on greater significance. Time is now counted from the start of dialysis rather than date of listing. Long time dialysis patients, those most likely to develop RCC, are therefore among the soonest transplanted. We reviewed our 15-year history of RCC diagnoses and correlated subtype, grade and stage with clinical outcomes for both ESRD patients and sporadic tumors. Our intention was to find evidence for or against changing ATS guidelines and instituting a watch and wait period for RCC before transplant.

*Methods: We reviewed charts and tumor slides for all RCC diagnosed during a 15-year period (2002-2017). The pathologic characteristics assessed were: histologic subtype; tumor size; grade; and pathologic staging. The clinical data recorded were: ESRD status; renal failure cause; dialysis time; transplanted or not; immunosuppressive medication; symptomatic or incidental; treatment; and recurrence. 87 patients were identified. Analyses were based on differences between patients with and without ESRD, while correlating tumor subtype, size and grade with patient outcomes. The outcome of interest was recurrence.

*Results: There were no differences in tumor staging or grading between ESRD and non-ESRD groups (Table 1). However, further analysis showed overall recurrence was more frequent in higher grade tumors (66.7% vs. 22.2%, p=0.038). Among ESRD patients with recurrence, there was increased total time dialysis time (17.75 years vs. 6.0 years, p=0.024). In subanalysis of ESRD patients with clear-cell (CC) histology and < 5 cm tumors, recurrence was slightly more frequent compared to non-ESRD patients (33.3% vs. 0.0%, p=0.046).

*Conclusions: The CCRCC subtype should require a wait period before transplant regardless of tumor size at diagnosis.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Laskar DB, Zeng J, Sharma S, Jr MTSmith, Nicastri AD, Levitan D, Maglantay R, John D, Gottesman SR. Renal Cell Carcinoma in Dialysis Patients: Criteria for Transplant Wait List Inclusion [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/renal-cell-carcinoma-in-dialysis-patients-criteria-for-transplant-wait-list-inclusion/. Accessed May 8, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences